Metagenomi wins FDA IND clearance for MGX-001 in hemophilia A; Q3 cash $101.7M runway into 2028

Metagenomi Therapeutics, Inc.

FDA cleared the IND for MGX-001; the INTEGR8 Phase 1/2 trial in adults with moderately severe to severe hemophilia A is planned to start in 1H 2027.
Initial safety, tolerability and Factor VIII activity data are expected in 2H 2027; additional preclinical data will be presented at ASH on Dec. 14, 2026 (Abstract 952).
Cash, cash equivalents and available-for-sale marketable securities were $101.7 million as of Sept. 30, 2026, with runway expected into 2028.
Q3 R&D expense was $17.5 million vs. $25.3 million a year earlier; G&A was $6.9 million, including a $1.2 million one-time net litigation settlement, vs. $6.2 million.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.